BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
Danylo Kaminskyy, Anna Kryshchyshyn, Roman Lesyk. 5-Ene-4-thiazolidinones – An efficient tool in medicinal chemistryEuropean Journal of Medicinal Chemistry 2017; 140: 542 doi: 10.1016/j.ejmech.2017.09.031
Guoxing Soon, Zhiwei Zhang, Yi Tsong, Lei Nie. Assessing overall evidence from noninferiority trials with shared historical dataStatistics in Medicine 2013; 32(14): 2349 doi: 10.1002/sim.5615
Yi Zhou, Na Chen, Xiaojing Liu, Shumei Lin, Wenjuan Luo, Min Liu. Kushenin induces the apoptosis of HCV-infected cells by blocking the PI3K-Akt-mTOR pathway via inhibiting NS5AExperimental Cell Research 2016; 345(1): 108 doi: 10.1016/j.yexcr.2016.05.002
J.-M. Sun, S.-J. Kim, G.-W. Kim, J.-K. Rhee, N. D. Kim, H. Jung, J. Jeun, S.-H. Lee, S. H. Han, C. S. Shin, J.-W. Oh. Inhibition of hepatitis C virus replication by Monascus pigment derivatives that interfere with viral RNA polymerase activity and the mevalonate biosynthesis pathwayJournal of Antimicrobial Chemotherapy 2012; 67(1): 49 doi: 10.1093/jac/dkr432
Reem Beleid, Donna Douglas, Norman Kneteman, Kamaljit Kaur. Helical Peptides Derived from Lactoferrin Bind Hepatitis C Virus Envelope Protein E2Chemical Biology & Drug Design 2008; 72(5): 436 doi: 10.1111/j.1747-0285.2008.00715.x
Philippe A. Gallay. Cyclophilin InhibitorsClinics in Liver Disease 2009; 13(3): 403 doi: 10.1016/j.cld.2009.05.002
Sean M. McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvirExpert Review of Clinical Pharmacology 2016; 9(2): 287 doi: 10.1586/17512433.2016.1129272
Yun-Ping Lim, Cheng-Yuan Peng, Wen-Ling Liao, Dong-Zong Hung, Ni Tien, Cing-Yu Chen, Shih-Yu Chang, Ching-Yao Chang, Fuu-Jen Tsai, Lei Wan. Genetic variation inNOS2Ais associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese ChineseJournal of Medical Virology 2013; 85(7): 1206 doi: 10.1002/jmv.23598
Matthew A. Gregory, Michael Bobardt, Susan Obeid, Udayan Chatterji, Nigel J. Coates, Teresa Foster, Philippe Gallay, Pieter Leyssen, Steven J. Moss, Johan Neyts, Mohammad Nur-e-Alam, Jan Paeshuyse, Mahmood Piraee, Dipen Suthar, Tony Warneck, Ming-Qiang Zhang, Barrie Wilkinson. Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin FamilyAntimicrobial Agents and Chemotherapy 2011; 55(5): 1975 doi: 10.1128/AAC.01627-10
Ivan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infectionExpert Review of Anti-infective Therapy 2014; 12(9): 1033 doi: 10.1586/14787210.2014.940898
Hongwei Wang, Haili Gao, Shupeng Duan, Xinwen Song. Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathwayVirus Research 2015; 208: 7 doi: 10.1016/j.virusres.2015.05.002
Stephanie Jiménez Irausquin, Austin L. Hughes. Distinctive pattern of sequence polymorphism in the NS3 protein of hepatitis C virus type 1b reflects conflicting evolutionary pressures Journal of General Virology 2008; 89(8): 1921 doi: 10.1099/vir.0.2008/000992-0
Amira A. Boseila, Amal Y. Abdel-Reheem, Emad B. Basalious, Abdelwahab Omri. Design of bile-based vesicles (BBVs) for hepatocytes specific delivery of Daclatasvir: Comparison of ex-vivo transenterocytic transport, in-vitro protein adsorption resistance and HepG2 cellular uptake of charged and β-sitosterol decorated vesiclesPLOS ONE 2019; 14(7): e0219752 doi: 10.1371/journal.pone.0219752
Mohamed A.H. Ismail, Dalal A. Abou El Ella, Khaled A.M. Abouzid, Amr H. Mahmoud. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivativesBioorganic & Medicinal Chemistry 2012; 20(7): 2455 doi: 10.1016/j.bmc.2012.01.031
Usman Ali Ashfaq, Muhammad Ansar, Muhammad Tahir Sarwar, Tariq Javed, Sidra Rehman, Sheikh Riazuddin. Post-transcriptional inhibition of hepatitis C virus replication through small interference RNAVirology Journal 2011; 8(1) doi: 10.1186/1743-422X-8-112
Sumalee Thitinan, Jason T. McConville. Interferon alpha delivery systems for the treatment of hepatitis CInternational Journal of Pharmaceutics 2009; 369(1-2): 121 doi: 10.1016/j.ijpharm.2008.11.027
Maria Letizia Barreca, Nunzio Iraci, Giuseppe Manfroni, Violetta Cecchetti. Allosteric inhibition of the hepatitis C virus NS5B polymerase:in silicostrategies for drug discovery and developmentFuture Medicinal Chemistry 2011; 3(8): 1027 doi: 10.4155/fmc.11.53
Frank Wagner, Robert Thompson, Constantino Kantaridis, Paul Simpson, Philip J. F. Troke, Shyla Jagannatha, Srividya Neelakantan, Vivek S. Purohit, Jennifer L. Hammond. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patientsHepatology 2011; 54(1): 50 doi: 10.1002/hep.24342
William W. Shields, Paul J. Pockros. Novel drugs for hepatitis C virusCurrent Hepatitis Reports 2009; 8(2): 52 doi: 10.1007/s11901-009-0008-8
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infectionExpert Opinion on Investigational Drugs 2014; 23(4): 561 doi: 10.1517/13543784.2014.892581
Carolin Wohlfarth, Thomas Efferth. Natural products as promising drug candidates for the treatment of hepatitis B and CActa Pharmacologica Sinica 2009; 30(1): 25 doi: 10.1038/aps.2008.5
Mozhgan Afrasiabi, Seyed Younes Hosseini, Ramin Yaghobi, Mohammad-Reza Fattahi, Maryam Ardebili, Mahboobeh Khodadad. Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of IranJundishapur Journal of Microbiology 2015; 8(10) doi: 10.5812/jjm.24965
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virusExpert Opinion on Investigational Drugs 2014; 23(9): 1211 doi: 10.1517/13543784.2014.921680
Mahmoud Mohamed Bahgat, Ahmed Atef Ibrahim, Dina Nadeem Abd-Elshafy, Ahmed Atef Mesalam, Hossam Eid Gewaid, Amany Abd-Elghany Ismaeil, Ahmed Mohamed El-Waseef, Amany Sayed Maghraby, Ahmed Barakat Barakat, Mohamed Abd-Elhafez El-Far, Hossam El-Din Ahmed Ghanem, Amro Mahmoud Mohamed, Mohamed Ahmed Ali. Characterization of NS3 protease from an Egyptian HCV genotype 4a isolateArchives of Virology 2009; 154(10): 1649 doi: 10.1007/s00705-009-0500-z
Phillip A Furman, Angela M Lam, Eisuke Murakami. Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trendsFuture Medicinal Chemistry 2009; 1(8): 1429 doi: 10.4155/fmc.09.88
Robert Flisiak, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda. Emerging treatments for hepatitis CExpert Opinion on Emerging Drugs 2013; 18(4): 461 doi: 10.1517/14728214.2013.847089
Jerzy Jaroszewicz, Robert Flisiak, Geoffrey Dusheiko. A pill for HCV - myth or foreseeable future?Liver International 2014; 34(1): 6 doi: 10.1111/liv.12294
Yuichi HIRATA, Masayuki SUDOH, Michinori KOHARA. Suppression of Hepatitis C Virus (HCV) Replication with Serine Palmitoyltransferase InhibitorYAKUGAKU ZASSHI 2010; 130(2): 157 doi: 10.1248/yakushi.130.157
Ivan Gentile, Maria Aurora Carleo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virusExpert Opinion on Investigational Drugs 2010; 19(1): 151 doi: 10.1517/13543780903501505
Asmaa M. Abdel-Aziz, Mohamed A. Ibrahim, Azza A. El-Sheikh, Maha Y. Kamel, Nagwa M. Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem. Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver FibrosisJournal of Clinical and Experimental Hepatology 2018; 8(1): 15 doi: 10.1016/j.jceh.2017.06.006
Robert A. Fridell, Dike Qiu, Chunfu Wang, Lourdes Valera, Min Gao. Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System Antimicrobial Agents and Chemotherapy 2010; 54(9): 3641 doi: 10.1128/AAC.00556-10